John B. Bode - 29 May 2025 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting relationship: Director
Issuer ticker: ZVRA
Reported as of: 29 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 May 2025, 21:38:03 UTC
Prior SEC filing: 21 Mar 2025
Next SEC filing: 20 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode

Key filing fact

John B. Bode filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 30 May 2025.

Key facts

This page summarizes John B. Bode's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 May 2025, 21:38.

Change

Previous filing in this sequence was filed on 21 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001612084 Primary reporting owner

Bode John B

Relationship: Director
Address: C/O ZEVRA THERAPEUTICS, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode
Signature date: 30 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $8.62
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025.

Footnote F2

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

Footnote F3

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.